SHERIDAN, WYOMING – May 7, 2025 – Intuitive, a global leader in minimally invasive care and robotic-assisted surgery, has announced that its SureForm 45 stapler has received FDA clearance for use with the da Vinci SP surgical system. The stapler is now approved for thoracic, colorectal, and urology procedures, marking a significant milestone in robotic surgical technology.
SHERIDAN, WYOMING – May 7, 2025 – Olympus Corporation has announced key changes to its leadership structure, including the appointment of Bob White as a new Representative Executive Officer, President, and Chief Executive Officer, effective June 1, 2025. The company also revealed a change in the responsibilities of Yasuo Takeuchi, who will continue in his roles as Director, Representative Executive Officer, Executive Chairperson, and ESG Officer. These changes come as part of Olympus’s ongoing efforts to drive its transformation and growth in the global MedTech sector.
SHERIDAN, WYOMING – May 7, 2025 – Baxter International Inc., a global leader in advancing surgical innovation, has announced the launch of its Hemopatch Sealing Hemostat with room temperature storage at a symposium in Vienna, Austria. This new product evolution significantly improves accessibility for surgeons, offering a practical and effective solution for controlling bleeding and preventing leakage during surgery. The product is now available for order throughout Europe, marking a key step forward in Baxter’s ongoing commitment to enhancing patient care.
SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW), a global leader in structural heart innovation, will announce its operating results for the first quarter ending March 31, 2025, after market close on Wednesday, April 23, 2025. The company will then host a conference call at 5:00 p.m. ET that same day to discuss these results in detail, providing insights into its financial performance and future strategic direction.
Conference Call Details and Participation
SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW) today unveiled new eight-year clinical data, confirming the exceptional long-term performance of its RESILIA tissue technology in aortic surgical valves. The data demonstrate significant improvements in patient outcomes, reinforcing the company's leadership in structural heart solutions.
SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW), a global leader in structural heart innovation, has announced its financial results for the first quarter ended March 31, 2025. The company delivered impressive growth across key product categories, including Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT), positioning itself for continued success in the structural heart market.
SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW) has announced the U.S. Food and Drug Administration (FDA) approval of its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for use in patients with asymptomatic severe aortic stenosis (AS). This groundbreaking approval marks the first-ever FDA authorization for TAVR in asymptomatic patients, potentially transforming the treatment landscape for those with this critical condition.
SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW) has announced its participation in the highly anticipated BofA Securities 2025 Health Care Conference, scheduled for Tuesday, May 13, 2025. The company's leadership, including CEO Bernard Zovighian and CFO Scott Ullem, will take part in a fireside chat at 10:40 a.m. Pacific Time. The discussion will be accessible to investors and healthcare professionals through a live webcast available on the Edwards Lifesciences investor relations website at http://ir.edwards.com.
SHERIDAN, WYOMING – May 7, 2025 – A new randomized controlled trial (RCT) has revealed significant advancements in rotator cuff repair, showing that augmentation with the REGENETEN Bioinductive Implant can substantially reduce the risk of re-tears, offering hope for better outcomes in patients undergoing full-thickness rotator cuff repairs. The study's findings have the potential to set a new standard of care in orthopedic surgery.
SHERIDAN, WYOMING – May 7, 2025 – The growing prevalence of rotator cuff tears, coupled with increasing patient expectations, has sparked a reevaluation of traditional surgical approaches. With more than 750,000 rotator cuff repairs performed annually in the U.S. and the number rising steadily, it’s clear that surgical interventions must evolve to meet the challenges of faster recovery times, improved functional outcomes, and better patient satisfaction.